FDA 483 OBSERVATION · #411 OF 1,000 MOST-CITED
Specifications met - test, examinations; compliance
FDA cited this observation 48 times across 45 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.2× the rate of the average FDA-cited firm (26.7% vs 8.3%), across 45 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for identity.
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for identity, purity, strength and composition.
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for limits on contamination that may adulterate or that may lead to adulteration of the dietary supplement.
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for identity, purity, strength and composition.
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for identity, purity, strength and composition.
You did not conduct appropriate tests or examinations to determine compliance with the specifications established for identity, purity, strength and composition.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.